Agenus Inc. (AGEN)
-NasdaqCM 4.05 
0.02(0.50%) 9:49AM EDT - Nasdaq Real Time Price
| Prev Close: | 4.03 |
|---|
| Open: | 4.00 |
|---|
| Bid: | 4.00 x 1000 |
|---|
| Ask: | 4.05 x 400 |
|---|
| 1y Target Est: | 10.63 |
|---|
| Beta: | 2.29 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 4.00 - 4.05 |
|---|
| 52wk Range: | 3.37 - 5.99 |
|---|
| Volume: | 10,857 |
|---|
| Avg Vol (3m): | 162,325 |
|---|
| Market Cap: | 114.63M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.13 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Agenus begins enrollment in NCI-Sponsored randomized trial of Prophage G-200theflyonthewall.com(Wed, May 22)
- Agenus Announces Initiation of Enrollment in NCI-Sponsored Randomized Trial of Prophage G-200 Vaccine With Avastin in Treatment of Brain TumorsGlobeNewswire(Wed, May 22)
- AGENUS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsEDGAR Online(Wed, May 22)
- AGENUS INC FinancialsEDGAR Online Financials(Fri, May 17)
- AGENUS INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Fri, May 10)
- Positive Phase 2 Data from Agenus' Brain Cancer Vaccine Presented at Plenary Session of American Academy of Neurological Surgeons MeetingGlobeNewswire(Wed, May 1)
- AGENUS INC Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Wed, May 1)
- Agenus: Near-Term Drivers With A Market Opportunity Over $17 Billionat Seeking Alpha(Mon, Apr 29)
- Agenus' CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Wed, Apr 24)
- Quickly Approaching Biopharma Catalyst Eventsat Seeking Alpha(Wed, Apr 24)
- Q1 2013 Antigenics Inc. Earnings Release - Before Market OpenCCBN(Wed, Apr 24)
- Agenus Reports First Quarter 2013 Financial ResultsGlobeNewswire(Wed, Apr 24)
- AGENUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online(Wed, Apr 24)
- An Industry Outlook With Analyst Vernon Bernardinoat Seeking Alpha(Mon, Apr 22)
- Agenus to Report First Quarter 2013 Financial Results on April 24, 2013; Conference Call to FollowGlobeNewswire(Thu, Apr 18)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 30.87 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.96 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.22 |
|---|
| Mean Recommendation*: | 1.8 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Agenus Inc., a biotechnology company, engages in developing and commercializing technologies to treat cancers and infectious diseases. Its technology portfolio consists of saponin adjuvant based technologies and heat shock protein based technologies.
View More